United States - NIA Central Biorepository - Biological Specimens Storage

Description

Added: Apr 10, 2019 2:53 pm

The National Institutes of Health (NIH), National Institute on Aging (NIA) intends to negotiate, under authority of FAR 6.302-1, on a noncompetitive, sole source basis, with Precision Bioservices, Inc., Frederick, Maryland.

This notice of intent is not a request for competitive proposals. A solicitation document will not be issued, and proposals will not be requested. However, responsible sources may express their interest by submitting a capability statement or proposal. All capability statements or proposals received within this notice's response date will be considered by the Government. A determination by the Government not to complete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
BACKGROUND
NOTE: This acquisition is related to the NIA Central Biorepository-Data Coordination and Systems Management under contract HHSN271201800021C.
The National Institute on Aging (NIA) at the National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS), conducts and funds various longitudinal and clinical studies on aging that generate or have generated a collection of biological specimens (biospecimens) and related phenotypic and clinical data/resources pertaining to these research activities. The NIA's Division of Geriatrics and Clinical Gerontology has recently established the NIA Central Biorepository (AgingResearchBiobank) to provide a state-of-the-art inventory system for the storage and distribution of biospecimens and related resources. All of these activities are in support of future research initiatives. The collection of patient and control biospecimens from many different studies funded by NIA in a single repository is a valuable resource with which researchers can more rapidly validate clinical hypotheses and algorithms for clinical decision making. These collections considerably contribute to advancing the development of prognostics, markers, and therapeutics for conditions related to aging and to a better understanding of the aging process.
Currently, approximately 1.8 million biospecimens are included in the AgingResearchBiobank, containing the following types of samples: plasma, serum, DNA, urine, EBV Cells & Cell Pellets, and buccal cells.
The biospecimens to be stored in the AgingResearchBiobank were collected over many years from studies that carefully selected subjects and are available in a finite quantity. Each biospecimen is unique and cannot be replaced if lost, damaged, or contaminated. It is very important that these biospecimens be stored under optimal conditions, which vary from type to type of biospecimen.
The Contractors responsible for the NIA Central Biorepository Biological Specimens Storage and for the NIA Central Biorepository Data Coordination and Systems Management shall collaborate to develop tools to facilitate management and use of the NIA Central Biorepository resources.
PURPOSE
NIA intends to negotiate on a noncompetitive, sole source basis, with Precision Bioservices, Inc., Frederick, Maryland under contract HHSN271201800020C to increase the total collection of biospecimens for Optional Task Area A and include new additional study collections for Optional Task Areas B-E to store, manage and distribute specimens from these study collections.
OPTIONAL TASK AREA A - Inclusion of an estimated total of 69,752 biospecimens composed of serum (47,310); DNA (6,600); whole blood (500); urine (14,193); buffy coat (411) which are currently at facilities in different locations: Minneapolis, MN; Pittsburgh, PA; San Diego, CA; San Francisco, CA.
OPTIONAL TASK AREA B - Inclusion of an estimated total of 260,900 samples composed of serum (181,000); urine (66,000); blood (11,100); plasma (2,800) which are currently located at facilities in three different locations Bethesda, Maryland; Portland, Oregon, and Birmingham, Alabama.
OPTIONAL TASK AREA C - Inclusion of an estimated total of 38,149 samples composed of serum (30,932); RNA (1,224); DNA (611) which are currently located at a facility in Burlington, Vermont.
OPTIONAL TASK AREA D - Inclusion of an estimated total of 7,000 samples composed of plasma (6,500); cerebrospinal fluid (CSF, 500) which are currently located at a facility in Boston, Massachusetts.
OPTIONAL TASK AREA E - Inclusion of an estimated total of 12,827 samples composed of EDTA (6,047); serum (4,607); PBM Cells (1426); packed cells (747)) which are currently located at a facility in Burlington, Vermont.
OTHER IMPORTANT CONSIDERATIONS
(1) The Government is expected to use procedures in FAR Part 6.302-1 and (2) The North American Industry Classification System (NAICS) Code 541990 with a size standard of $15 million.
DISCLAIMER AND IMPORTANT NOTES
This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation.
CONFIDENTIALITY
No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

Opportunity closing date

24 April 2019

Value of contract

to be confirmed